Gary S. Jacob Purchased 5,680 Shares of Synergy Pharmaceuticals Inc (SGYP) Shares

Gary S. Jacob Purchased 5,680 Shares of Synergy Pharmaceuticals Inc (SGYP) Shares

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) CEO Gary S. Jacob bought 5,680 shares of the business’s stock in a transaction dated Friday, May 26th. The shares were acquired at an average cost of $3.52 per share, for a total transaction of $19,993.60. Following the transaction, the chief executive officer now directly owns 402,679 shares in the company, valued at approximately $1,417,430.08. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) traded up 1.15% on Tuesday, reaching $3.52. The company’s stock had a trading volume of 968,524 shares. The company’s market capitalization is $791.82 million. Synergy Pharmaceuticals Inc has a 52 week low of $3.35 and a 52 week high of $7.15. The firm’s 50 day moving average price is $4.08 and its 200-day moving average price is $5.20.

Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.07. The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.10 million. On average, equities analysts predict that Synergy Pharmaceuticals Inc will post ($0.91) EPS for the current year.

SGYP has been the topic of several research analyst reports. BTIG Research reissued a “buy” rating and set a $11.00 target price on shares of Synergy Pharmaceuticals in a research report on Saturday, April 22nd. Rodman & Renshaw reaffirmed a “buy” rating and set a $18.00 price target on shares of Synergy Pharmaceuticals in a research report on Wednesday, March 29th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Synergy Pharmaceuticals in a research report on Tuesday, March 28th. Oppenheimer Holdings Inc. set a $10.00 price target on Synergy Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, March 2nd. Finally, Canaccord Genuity set a $13.00 price target on Synergy Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, March 2nd. Three analysts have rated the stock with a sell rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $11.50.

Several hedge funds have recently made changes to their positions in SGYP. Credit Suisse AG boosted its stake in shares of Synergy Pharmaceuticals by 202.3% in the first quarter. Credit Suisse AG now owns 728,352 shares of the biopharmaceutical company’s stock worth $3,395,000 after buying an additional 487,434 shares during the last quarter. Family Management Corp boosted its stake in shares of Synergy Pharmaceuticals by 159.4% in the first quarter. Family Management Corp now owns 41,500 shares of the biopharmaceutical company’s stock worth $193,000 after buying an additional 25,500 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Synergy Pharmaceuticals by 5.6% in the first quarter. Metropolitan Life Insurance Co. NY now owns 134,855 shares of the biopharmaceutical company’s stock worth $628,000 after buying an additional 7,195 shares during the last quarter. Highbridge Capital Management LLC boosted its stake in shares of Synergy Pharmaceuticals by 19.8% in the first quarter. Highbridge Capital Management LLC now owns 62,106 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 10,267 shares during the last quarter. Finally, Kingdon Capital Management L.L.C. boosted its stake in shares of Synergy Pharmaceuticals by 42.7% in the first quarter. Kingdon Capital Management L.L.C. now owns 2,237,701 shares of the biopharmaceutical company’s stock worth $10,428,000 after buying an additional 669,214 shares during the last quarter. Institutional investors and hedge funds own 55.36% of the company’s stock.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:SGYP”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment